Agios Pharmaceuticals’ (AGIO) “Outperform” Rating Reaffirmed at Raymond James

Raymond James reaffirmed their outperform rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a report released on Thursday, MarketBeat Ratings reports. They currently have a $51.00 price target on the biopharmaceutical company’s stock.

AGIO has been the topic of a number of other research reports. Leerink Partnrs cut Agios Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Friday, September 27th. StockNews.com cut Agios Pharmaceuticals from a hold rating to a sell rating in a research note on Monday, August 5th. Royal Bank of Canada reiterated an outperform rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, September 19th. Leerink Partners lowered Agios Pharmaceuticals from an outperform rating to a market perform rating and lowered their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Finally, Cantor Fitzgerald reiterated an overweight rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of Hold and an average price target of $52.20.

Agios Pharmaceuticals Stock Up 2.3 %

AGIO opened at $41.82 on Thursday. The stock’s 50 day moving average price is $44.62 and its 200-day moving average price is $40.41. Agios Pharmaceuticals has a one year low of $19.80 and a one year high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) EPS for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The business had revenue of $8.60 million for the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The company’s quarterly revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.51) EPS. Equities analysts forecast that Agios Pharmaceuticals will post -4.87 earnings per share for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares in the company, valued at approximately $988,346.74. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Brian Goff sold 11,091 shares of the stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total value of $474,140.25. Following the sale, the chief executive officer now owns 78,792 shares of the company’s stock, valued at approximately $3,368,358. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Caxton Associates LP lifted its holdings in shares of Agios Pharmaceuticals by 0.7% during the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after purchasing an additional 264 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Agios Pharmaceuticals by 0.8% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 39,248 shares of the biopharmaceutical company’s stock valued at $1,148,000 after purchasing an additional 314 shares during the last quarter. CANADA LIFE ASSURANCE Co lifted its holdings in shares of Agios Pharmaceuticals by 1.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 31,144 shares of the biopharmaceutical company’s stock valued at $911,000 after purchasing an additional 540 shares during the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $37,000. Finally, Quest Partners LLC purchased a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at $40,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.